RxDoctor Payments Data

Synobra Alexander

Family · Bronx, NYNPI 1710670369

Payments from drug & device makers

$859in general payments, 2019–2025

Across 31 payments — averaging $27.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$185
  • Lilly USA, LLC$176
  • GSK$167
  • Corcept Therapeutics$144
  • Novartis$88
  • Amgen$33
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$859100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$859 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$21,657
Medicare patients
62
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin58$47,798
OzempicSemaglutide21$22,832
MounjaroTirzepatide17$21,061
EliquisApixaban23$18,215
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,259
JanuviaSitagliptin Phosphate14$9,551
Albuterol Sulfate HfaAlbuterol Sulfate53$2,589
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,318
Atorvastatin Calcium80$659
Omeprazole57$622
Gabapentin37$572
Metoprolol Succinate44$518
Ammonium Lactate13$497
Nifedipine ErNifedipine16$457
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide15$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$22,83221 claims
Lilly USA, LLCMounjaro$176$21,06117 claims
GSKTrelegy Ellipta$167$17,25920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,883 family providers in New York.

Other family in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →